Teva executive sells shares to cover tax withholding

Teva Pharmaceutical Industries executive Eric A. Hughes, Executive Vice President, Global R&D and Chief Medical Officer, exercised 52,744 restricted share units into ordinary shares on August 3, 2026.

Accepted by SEC EDGAR 08/05/2026 - 04:02 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Teva Pharmaceutical Industries executive Eric A. Hughes, Executive Vice President, Global R&D and Chief Medical Officer, exercised 52,744 restricted share units into ordinary shares on August 3, 2026. He then sold 25,578 ordinary shares at a weighted average of $34.8757 per share under a Rule 10b5-1 trading plan to cover tax withholding obligations related to the RSU vesting.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Hughes Eric A

Role See "Remarks"

Sold 25,578 shs ($892K)

Approx. gross sale proceeds $892K

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units F2, F6, F1	52,744	$0.00	$0.00
Exercise	Ordinary Shares F1, F2	52,744	--	--
Sale	Ordinary Shares F1, F3, F4, F5	25,578	$34.8757	$892K

Holdings After Transaction: Restricted Share Units — 0 contracts (Direct); Ordinary Shares — 134,877 shares (Direct)

Footnotes (6)

1. F1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
2. F2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
3. F3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.
4. F4. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
5. F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.66 to $35.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
6. F6. Restricted share units were granted on August 1, 2022, with 52,742 vested on each of August 1, 2023, August 1, 2024 and August 1, 2025, and 52,744 vested on August 1, 2026.

Key Figures

RSUs exercised: 52,744 units Shares sold for taxes: 25,578 shares Weighted average sale price: $34.8757 per share +3 more

6 metrics

RSUs exercised 52,744 units Restricted share units converted into ordinary shares on August 3, 2026

Shares sold for taxes 25,578 shares Ordinary shares sold to cover tax withholding on RSU vesting

Weighted average sale price $34.8757 per share Average price for multiple sale transactions on August 3, 2026

10b5-1 plan adoption date November 10, 2025 Rule 10b5-1 trading plan governing the sale transaction

RSU grant date August 1, 2022 Grant date of restricted share units vesting through August 1, 2026

Final RSU vesting tranche 52,744 units Final tranche vested on August 1, 2026 under the 2022 RSU grant

Key Terms

Restricted Share Units, Rule 10b5-1 trading plan, weighted average price, American Depositary Shares

4 terms

Restricted Share Units financial

"Each restricted share unit represents a contingent right to receive one ordinary share."

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

Rule 10b5-1 trading plan regulatory

"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported is a weighted average price for multiple sale transactions."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

American Depositary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares, each representing one Ordinary Share."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Teva (TEVA) executive Eric A. Hughes report?

Eric A. Hughes reported exercising 52,744 restricted share units into Teva ordinary shares and selling 25,578 shares. The sale on August 3, 2026 was linked to RSU vesting and conducted under a Rule 10b5-1 trading plan to address tax obligations.

How many Teva (TEVA) shares did Eric A. Hughes sell and at what price?

He sold 25,578 ordinary shares of Teva at a weighted average price of $34.8757 per share. The shares were sold in multiple trades at prices ranging from $34.66 to $35.07, as disclosed in the transaction footnote.

Were Eric A. Hughes’s Teva (TEVA) share sales made under a Rule 10b5-1 plan?

Yes. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Eric A. Hughes on November 10, 2025. This plan-based structure indicates the sale timing was pre-arranged rather than discretionary at the time of execution.

Why were Eric A. Hughes’s Teva (TEVA) shares sold on August 3, 2026?

The 25,578 shares were sold to cover tax withholding obligations arising from the vesting of restricted share units. The company notes these shares represent the amount required to satisfy withholding taxes tied specifically to the RSU vesting event.

What RSU grant and vesting schedule did Eric A. Hughes disclose at Teva (TEVA)?

Restricted share units were granted on August 1, 2022. Tranches of 52,742 units vested on August 1 of 2023, 2024 and 2025, and a final tranche of 52,744 units vested on August 1, 2026, leading to the reported settlement.

How are Teva (TEVA) ordinary shares represented in the U.S. market for this transaction?

The filing notes that Teva’s Ordinary Shares may be represented by American Depositary Shares (ADS), with each ADS currently representing one Ordinary Share. The reported RSU settlement and sale relate to these ordinary shares or their ADS equivalents.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hughes Eric A

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV 6944020

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See "Remarks"

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	08/03/2026		M		52,744	A	(2)	160,455	D
Ordinary Shares(1)	08/03/2026		S(3)		25,578(4)	D	$34.8757(5)	134,877	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	08/03/2026		M			52,744	(6)	(6)	Ordinary Shares(1)	52,744	$0	0	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.

4. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.66 to $35.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

6. Restricted share units were granted on August 1, 2022, with 52,742 vested on each of August 1, 2023, August 1, 2024 and August 1, 2025, and 52,744 vested on August 1, 2026.

Remarks:

Executive Vice President, Global R&D and Chief Medical Officer.

	/s/ Dov Bergwerk as attorney-in-fact for Eric A. Hughes	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)